Correspondence | Published:

Shaping the future of safer innovative drugs in Europe

Nature Biotechnology volume 29, pages 789790 (2011) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Anonymous. Nat. Biotechnol. 29, 551 (2011).

  2. 2.

    Chem. Res. Toxicol. 19, 1257–1262 (2006).

  3. 3.

    , , & Expert Opin. Drug Metab. Toxicol. 5, 1–14 (2009).

  4. 4.

    Drug Discov. Today 15, 16–22 (2010).

  5. 5.

    & Environ. Health Perspect. 118, 1047–1050 (2010).

  6. 6.

    (ed.). Handbook of Chemoinformatics—From Data to Knowledge (Wiley-VCH: Weinheim, 2003).

  7. 7.

    J. Med. Chem. 49, 6429–6434 (2006).

  8. 8.

    et al. Expert Opin. Drug Metab. Toxicol. 6, 851–861 (2010).

  9. 9.

    , , & Rapid Commun. Mass Spectrom. 24, 3127–3138 (2010).

  10. 10.

    & J. Chem. Inf. Model. 45, 160–169 (2005).

  11. 11.

    , & J. Comput. Aided Mol. Des. 20, 773–788 (2006).

  12. 12.

    , , & Nat. Biotechnol. 26, 983–984 (2008).

  13. 13.

    & Expert Opin. Drug Metab. Toxicol. 6, 1253–1263 (2010).

Download references

Author information

Affiliations

  1. Chemotargets, IMIM-Hospital del Mar, and University Pompeu Fabra, Barcelona, Catalonia, Spain.

    • Jordi Mestres
  2. Inte:Ligand, Vienna, Austria.

    • Sharon D Bryant
  3. Lead Molecular Design, Sant Cugat del Vallès, Spain.

    • Ismael Zamora
  4. Molecular Networks, Erlangen, Germany.

    • Johann Gasteiger

Authors

  1. Search for Jordi Mestres in:

  2. Search for Sharon D Bryant in:

  3. Search for Ismael Zamora in:

  4. Search for Johann Gasteiger in:

Competing interests

J.M. is the president of Chemotargets, S.D.B. is the CEO of Inte:Ligand, I.E. is the CEO of Lead Molecular Design and J.G. is the president of Molecular Networks.

Corresponding author

Correspondence to Jordi Mestres.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.1973

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing